KOSPIBiotech & Pharma002630

Orientbio

₩1,167▼ 1.85%2026-11-18 close
Market Cap
₩34.6B
Turnover
₩93,720,533
Volume
80K
Shares out.
29.7M
PER
—
PBR
0.5×
EPS
-₩25
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Quarterly Turnaround, but Annual Losses Persist for Three Years

Orientbio swung to a quarterly operating profit in 2026 Q2, yet its operating loss for the fiscal year ended March 2026 widened to KRW 4.13 billion, and it returned to an operating loss in 2026 Q3.

  1. 1

    After an operating loss of KRW 259 million in 2026 Q1, Orientbio posted an operating profit of KRW 50.06 million in 2026 Q2.

  2. 2

    The operating loss for the fiscal year ended March 2026 was KRW 4.13 billion, with an operating margin of -13.9%, marking three consecutive years of losses since the fiscal year ended March 2024.

  3. 3

    In 2026 Q3 the company recorded an operating loss of KRW 89 million and a net loss attributable to controlling shareholders of KRW 3.1 billion, returning to the red after the 2026 Q2 profit.

  4. 4

    Total equity stood at KRW 68.5 billion at the end of March 2026, with a debt ratio of 19.1% and a debt-free management stance.

  5. 5

    Over the four quarters from 2025 Q4 to 2026 Q3, the net loss attributable to controlling shareholders totaled KRW 637 million, so earnings-based multiples are not calculable.

02

Business structure

Orientbio is a bio research infrastructure company whose business rests on two pillars: research animal supply and contract non-clinical research (CRO).

One press report noted that the company is the only domestic producer of internationally standardized research animals and described its supply of high-quality biological materials since a 1999 technology partnership with a US firm.

Its product range now covers rodents such as mice and rats, beagles, and primates, along with SPF research rabbits that the company began mass-producing domestically in August 2026. Technology partners include Charles River Laboratories, Covance, and Kitayama Labes of Japan, which form the basis of its supply lineup.

Its domestic production base in Gapyeong now runs as a single integrated operation covering production planning, animal housing, and quality control.

The primate CRO business rests on an exclusive business agreement with affiliate Orient Cam signed in July 2026, linking supply, study execution, quality assurance, and data analysis.

Its medium-term plan includes expanding research animal supply, reinforcing non-clinical support, developing disease models, and growing a drug discovery platform. In the pipeline is OND-1, a non-hormonal hair-loss candidate that received an IND clearance from the US FDA, alongside an AI-based non-clinical platform.

Customer concentration is low: the company reported that in 2026 Q2 (April to June, its fiscal Q1) its largest customer accounted for 6.0% of sales and the top five for about 22.5%. The company has operated without borrowings since 2022, with a debt ratio of about 19%.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩6.9B-₩700M−9.8%
2025Q4₩8.6B-₩1.6B−18.2%
2026Q1₩6.5B-₩300M−4.0%
2026Q2₩6.6B₩50,062,9120.8%
2026Q3₩6.8B-₩88,998,041−1.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023.03₩28.8B₩1.5B-₩12.4B5.0%−17.4%13.5%
2024.03₩28B-₩600M₩12.9B−2.3%15.1%14.0%
2025.03₩29.4B-₩3.1B-₩13.2B−10.5%−18.4%18.0%
2026.03₩29.8B-₩4.1B-₩4.6B−13.9%−6.7%19.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual sales moved from KRW 28.8 billion in the fiscal year ended March 2023 to KRW 28 billion in the fiscal year ended March 2024 (down 2.8% year on year), then rose to KRW 29.4 billion in the fiscal year ended March 2025 and KRW 29.8 billion in the fiscal year ended March 2026, marking two consecutive years of growth.

The fiscal year ended March 2026 was the largest year in the period from the fiscal year ended March 2023 through the fiscal year ended March 2026, with sales up 1.2%.

Operating profit fell from KRW 1.45 billion in the fiscal year ended March 2023 to an operating loss of KRW 646 million in the fiscal year ended March 2024, then to KRW 3.08 billion and KRW 4.13 billion in the next two years, marking three consecutive years of losses.

The operating margin declined from 5.0% in the fiscal year ended March 2023 to -13.9% in the fiscal year ended March 2026. A nine-month analysis of 2025 found that sales rose slightly while cost burdens shrank gross profit and widened the operating loss.

The company attributed the larger operating loss in the fiscal year ended March 2026 to a one-time asset valuation loss.

Net profit attributable to controlling shareholders swung to KRW 12.9 billion in the fiscal year ended March 2024, then posted losses of KRW 13.2 billion and KRW 4.57 billion in the following two years, marking two consecutive years of losses.

Net profit including non-controlling interests was a loss of KRW 4.57 billion in the fiscal year ended March 2026. Operating cash flow was KRW 3.76 billion, KRW 752 million, and KRW 2.6 billion in the fiscal years ended March 2024, 2025, and 2026, respectively, rising in the latest year.

Quarterly sales were KRW 6.93 billion in 2025 Q3 and KRW 8.6 billion in 2025 Q4, fell to KRW 6.54 billion in 2026 Q1, then rose to KRW 6.59 billion in 2026 Q2 and KRW 6.77 billion in 2026 Q3, two consecutive quarters of growth.

The company credited the Gapyeong center consolidation and production efficiency for the turn from a KRW 259 million operating loss in 2026 Q1 to an operating profit of KRW 50.06 million in 2026 Q2.

Over the same period the company said its cost of sales ratio fell from 90.2% a year earlier to 69.0%, and total operating costs fell 29.7%. The 2026 Q2 net profit attributable to controlling shareholders of KRW 4.85 billion reflected a bad-debt provision reversal, according to the company's explanation.

In 2026 Q3, sales of KRW 6.77 billion were down 2.4% year on year, and the operating loss of KRW 89 million narrowed from a year earlier, while the net loss attributable to controlling shareholders of KRW 3.1 billion widened.

The net loss attributable to controlling shareholders over the four quarters from 2025 Q4 to 2026 Q3 totaled KRW 637 million.

05

Industry analysis

The research animal and non-clinical market that Orientbio serves depends on preclinical demand for validating drug candidates. The company says that continued development of biopharmaceuticals and gene therapies has raised demand for non-clinical studies using primates.

According to a report by E-Today, expanding development of antibody-drug conjugates and antibody therapeutics has sharply increased demand for primate testing to validate candidates.

The company argues that global supply of research primates is structurally constrained, which highlights the competitiveness of CRO providers with stable production bases.

On the supply side, domestic production of SPF research rabbits, which had depended on imports, has reduced import quarantine and transport risks, a point favorable to the company. The company describes its domestic production center on a site of about 25,000 pyeong as the largest in Korea.

Primate supply relies on a production base in Cambodia and an affiliate, which brings related-party dealings and dependence on overseas production. Competition from domestic and overseas CRO providers persists, and the company cites its primate exclusivity agreement as a point of differentiation.

In cycle terms, the business sits in a growth phase tied to drug development demand, but the speed at which that demand reaches reported results depends on contract timing.

06

Outlook

The company's medium-term strategy centers on expanding research animal supply, reinforcing non-clinical research support, developing disease models, and growing its drug discovery platform.

The primate CRO business aims to win studies from global pharmaceutical and biotech clients, based on the exclusive business agreement with Orient Cam signed in July 2026. The company has said it plans to use its Cambodian base to capture global non-clinical demand, including for antibody-drug conjugates.

Its AI non-clinical data initiative aims to accumulate pathology, blood, and toxicity data from primate studies in a database for toxicity and efficacy prediction. OND-1 is a hair-loss drug candidate that has received IND clearance from the US FDA, but no public timeline for its next development stage has been given.

As funding for business expansion, the company cited cash and cash equivalents of about KRW 38 billion, including short-term financial instruments, together with its debt-free stance, in an August 2026 announcement.

On the capital side, a 2-for-1 free reverse share consolidation took effect with a record date of September 4, 2026, which the company said was aimed at improving its capital structure and raising shareholder value. Whether SPF rabbit production contributes to revenue will be checked in upcoming periodic reports.

Whether the Gapyeong consolidation sustains the cost-ratio gains will be the key point in determining the direction of future results.

07

Valuation

PER
—
PBR
0.5×
ROE
-0.9%
EPS
-₩25
BPS
₩2,382
Dividend per share
₩0

Because net losses have continued over the most recent four quarters, earnings-based multiples are not calculable. The price-to-book ratio is below 1 times.

Total equity and the equity attributable to controlling shareholders were both KRW 68.5 billion at the end of March 2026, so the entire net asset base belongs to controlling shareholders.

Market capitalization sits below total equity, and how this gap is read depends largely on whether the asset base can generate earnings. Dividend payouts are below the industry average.

Over several years, the company has alternated between profit turnarounds and renewed losses, so the direction of earnings recovery is not yet settled. Apart from the net profit attributable to controlling shareholders in the fiscal year ended March 2024, few years show consistent earnings-based valuation support. Valuation is typically read together with earnings trends, asset composition, and pipeline progress.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Cost Structure Improvement

Operating profit in 2026 Q2 was KRW 50.06 million, a turnaround to profit. The company said its cost of sales ratio fell from 90.2% a year earlier to 69.0% over the same period. It attributed this to the Gapyeong center consolidation and production efficiency, and said total operating costs fell 29.7%.

Debt-Free Balance Sheet

The company has run without borrowings since 2022 and reported a debt ratio of about 19%. In an August 2026 announcement it said it held about KRW 38 billion in cash and cash equivalents, including short-term financial instruments. Total equity of KRW 68.5 billion at the end of March 2026 can be read as a buffer against financial shocks.

Primate CRO and SPF Rabbits

Structurally constrained supply of research primates favors CRO providers with stable production bases. The exclusive agreement with Orient Cam gives the company a system linking supply, study execution, quality assurance, and data analysis.

SPF research rabbits began domestic mass production in August 2026, which is expected to reduce reliance on imports.

09

Bear factors

Widening Annual Losses

The operating loss for the fiscal year ended March 2026 was KRW 4.13 billion, with an operating margin of -13.9%, and losses have widened each year since the fiscal year ended March 2024. The net loss attributable to controlling shareholders was KRW 4.57 billion.

The company pointed to a one-time asset valuation loss, but the pace of core profitability recovery is not yet visible in annual figures.

Losses Return in a Quarter

The operating loss in 2026 Q3 was KRW 89 million and the net loss attributable to controlling shareholders was KRW 3.1 billion, so the 2026 Q2 profit reversed within one quarter. Sales of KRW 6.77 billion were down 2.4% year on year.

The company said the 2026 Q2 net profit of KRW 4.85 billion reflected a bad-debt provision reversal, which limits how repeatable that profit is.

Unclear Contribution from New Businesses

New businesses such as the AI non-clinical platform and OND-1 are presented as medium-term growth drivers, but few figures are separately reported for them in the filed results. Sales for the fiscal year ended March 2026 were KRW 29.8 billion, up only 1.2% year on year. The contribution of these new businesses to results remains difficult to gauge in numbers.

10

Risk factors

Order and Client Volatility

CRO revenue depends on the development schedules and order flow of global pharmaceutical companies, so quarterly swings are possible. The 2026 Q3 sales decline from a year earlier illustrates this.

The company says it is actively pursuing overseas markets, but results from overseas client acquisition are not yet separately visible in filed figures.

Overseas Production and Related-Party Dependence

The primate supply base sits with affiliate Orient Cam and its Cambodian base, bringing dependence on overseas production and related-party dealings. The breeding and husbandry infrastructure in Cambodia was built by a group affiliate. Changes in local husbandry conditions or quarantine rules could affect supply timing.

Shrinking Equity and Reverse Share Consolidation

Total equity fell from KRW 71.8 billion at the end of March 2025 to KRW 68.5 billion at the end of March 2026, and continued losses could extend the decline. A 2-for-1 free reverse share consolidation took effect with a record date of September 4, 2026, presented as a means of improving the capital structure. The effect of the changed share count on trading and supply-demand will emerge over time.

11

What to watch next

  1. Around mid-February 2027

    Around the deadline for the 2026 Q4 (October to December) quarterly report, 45 days after quarter-end, check whether operating results stay in profit and whether the cost of sales ratio holds near 69%.

  2. Late June 2027

    The filing deadline for the annual report for the fiscal year ending March 2027 (90 days after year-end). Check whether the operating loss continues for a fourth year and whether primate CRO revenue becomes separately visible.

  3. Ad hoc disclosures from late 2026

    Use ad hoc disclosures such as primate CRO contract awards with Orient Cam and the next development step for OND-1 to gauge the potential contribution of new businesses to results.

12

Overall view

Orientbio's results for the fiscal year ended March 2026 showed the largest annual sales in the period, at KRW 29.8 billion, yet the company recorded an operating loss of KRW 4.13 billion and a net loss attributable to controlling shareholders of KRW 4.57 billion, marking three consecutive years of operating losses.

Lower cost ratios from the Gapyeong consolidation and production efficiency turned 2026 Q2 into an operating profit, but 2026 Q3 returned to operating and net losses.

This pattern shows that cost improvements can produce quarterly profits, yet it is not yet confirmed whether they are durable enough to reverse annual losses. On the financial side, the debt-free stance and total equity of KRW 68.5 billion provide a cushion, though equity has been declining through losses.

Newer businesses such as primate CRO and SPF rabbits have room to grow given supply conditions, but their contribution is not visible in filed results. Because earnings-based multiples are not calculable, valuation is best read together with asset composition and business progress.

The next checkpoints are the operating margin in the 2026 Q4 quarterly report and in the annual report for the fiscal year ending March 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. etoday.co.kr
  2. comp.wisereport.co.kr
  3. markets.hankyung.com
  4. vegannews.co.kr
  5. etoday.co.kr
  6. etoday.co.kr
  7. news.jkn.co.kr
  8. etoday.co.kr
  9. m.news.nate.com
  10. newspim.com
  11. valueline.co.kr
  12. comp.fnguide.com
  13. supple.kr
  14. m.news.nate.com
  15. digitaltoday.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis